Can you switch from Ajovy (fremanezumab) to another CGRP inhibitor?
Yes. Ajovy is a CGRP monoclonal antibody (mAb) for migraine prevention, and patients can generally switch to another CGRP inhibitor if Ajovy isn’t working, causes side effects, or becomes inconvenient to use. The other CGRP mAbs available in this class include Aimovig (erenumab) and Emgality (galcanezumab).
Because these medicines target the same overall pathway (CGRP or the CGRP receptor), switching is a common clinical approach, but the best choice depends on why you want to switch and your medical history.
What usually drives the switch—lack of benefit or side effects?
People typically switch from Ajovy for one of these reasons:
- Insufficient reduction in migraine days after an adequate trial
- Injection-site or other side effects
- Insurance/coverage or dosing preference
If you switched due to side effects, clinicians often consider whether the side effect is class-related or specific to Ajovy. Even within the same class, patient response can differ, so another CGRP mAb can still help.
How do Aimovig and Emgality differ from Ajovy?
Ajovy (fremanezumab) binds to CGRP itself.
Aimovig (erenumab) blocks the CGRP receptor.
Emgality (galcanezumab) binds to CGRP like Ajovy.
Because the binding target differs (ligand vs receptor), some patients who don’t respond well to one approach may respond to the other, but there’s no guarantee.
Is there a “washout” period when switching?
The safe interval depends on how your clinician wants to manage timing with respect to your next scheduled dose, your migraine pattern, and any prior adverse effects. Many clinicians switch without a long washout because these are long-acting mAbs, but the exact plan should come from your prescriber.
What should you tell your prescriber before switching?
Bring up:
- How long you have been on Ajovy and how many migraine days you had before vs during treatment
- Any side effects you had (and how severe they were)
- Your dosing schedule (monthly vs quarterly dosing, if applicable to your prescription)
- Other migraine preventives you’re using, since combinations can affect tolerability
What if you’ve already tried multiple CGRP inhibitors?
If you tried one CGRP mAb and didn’t benefit, switching to a different CGRP mAb is still reasonable in many cases. But if you’ve tried multiple CGRP inhibitors without benefit, clinicians sometimes consider non-CGRP preventives (for example, other classes of migraine preventives) rather than cycling through more CGRP mAbs.
Can you switch while pregnant or planning pregnancy?
Migraine prevention plans in pregnancy are highly individualized. If pregnancy is possible or planned, you should discuss switching (and timing) with your prescriber before making changes, because pregnancy safety considerations can affect which preventive options are favored.
If you share which CGRP inhibitor you’re considering (Aimovig or Emgality, or another), how long you’ve been on Ajovy, and what problem you’re trying to fix (not working vs side effects vs access), I can help you map the typical decision factors to your situation.